REAL WORLD COMPARISON OF MAJOR BLEEDING RISK AMONG NON-VALVULAR ATRIAL FIBRILLATION PATIENTS NEWLY INITIATED ON APIXABAN, WARFARIN, DABIGATRAN OR RIVAROXABAN: A 1:1 PROPENSITY-SCORE MATCHED ANALYSIS
Lip, Gregory, Keshishian, Allison, Kamble, Shital, Pan, Xianying, Burns, Leah, Mardekian, Jack, Masseria, Cristina, Bruno, Amanda, Phatak, HemantТом:
67
Мова:
english
Журнал:
Journal of the American College of Cardiology
DOI:
10.1016/s0735-1097(16)30883-x
Date:
April, 2016
Файл:
PDF, 401 KB
english, 2016
File converter
Більше результатів пошуку
More benefits 
